iopamidol · Bracco · NDA 018735, 020327
Isovue-300
Earliest generic entry, as listed · earliest of 2 marketed strengths
10 Oct 2028
1 of 2 marketed strengths has no unexpired patent or exclusivity listed.
Blocked by exclusivity: I-975.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 1 unexpired
| I-975 | new indication (3 years) | 10 Oct 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 018735 · 002 · RLD | injectable, injection | 61% | 10 Oct 2028 |
| 020327 · 003 · RLD | injectable, injection | 61% | open |